ATE537175T1 - Neue piperazino-dihydrothienopyrimidin-derivate - Google Patents
Neue piperazino-dihydrothienopyrimidin-derivateInfo
- Publication number
- ATE537175T1 ATE537175T1 AT08840365T AT08840365T ATE537175T1 AT E537175 T1 ATE537175 T1 AT E537175T1 AT 08840365 T AT08840365 T AT 08840365T AT 08840365 T AT08840365 T AT 08840365T AT E537175 T1 ATE537175 T1 AT E537175T1
- Authority
- AT
- Austria
- Prior art keywords
- dihydrothienopyrimidine
- derivatives
- piperazino
- new
- patient
- Prior art date
Links
- NBHGLBORHJRXFF-UHFFFAOYSA-N 1-piperazin-1-yl-2h-thieno[3,2-d]pyrimidine Chemical class C1CNCCN1N1C(C=CS2)=C2C=NC1 NBHGLBORHJRXFF-UHFFFAOYSA-N 0.000 title 1
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- -1 diastereomers Chemical class 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07118906 | 2007-10-19 | ||
| PCT/EP2008/063970 WO2009050236A1 (de) | 2007-10-19 | 2008-10-16 | Neue piperazino-dihydrothienopyrimidin-derivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE537175T1 true ATE537175T1 (de) | 2011-12-15 |
Family
ID=39154598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08840365T ATE537175T1 (de) | 2007-10-19 | 2008-10-16 | Neue piperazino-dihydrothienopyrimidin-derivate |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8486948B2 (enExample) |
| EP (1) | EP2215093B1 (enExample) |
| JP (1) | JP5563466B2 (enExample) |
| AT (1) | ATE537175T1 (enExample) |
| CA (1) | CA2702518A1 (enExample) |
| WO (1) | WO2009050236A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1847543A1 (de) | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
| JP5563466B2 (ja) | 2007-10-19 | 2014-07-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ピペラジノ−ジヒドロチエノピリミジン誘導体 |
| DK2610258T3 (da) | 2007-10-19 | 2014-11-10 | Boehringer Ingelheim Int | Substituerede piperidindihydrothienopyrimidiner |
| CN101827853A (zh) | 2007-10-19 | 2010-09-08 | 贝林格尔.英格海姆国际有限公司 | 杂环取代的哌嗪子基-二氢噻吩并嘧啶 |
| EP3176171A1 (en) | 2010-04-02 | 2017-06-07 | Ogeda Sa | Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders |
| US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
| US9802954B2 (en) | 2011-08-24 | 2017-10-31 | Boehringer Ingelheim International Gmbh | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma |
| EA029340B1 (ru) * | 2011-10-03 | 2018-03-30 | Огеда Са | ХИРАЛЬНЫЕ N-АЦИЛ-5,6,7,(8-ЗАМЕЩЕННЫЕ)-ТЕТРАГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНЫ КАК СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА NK-3, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПРИМЕНЕНИЯ ПРИ НАРУШЕНИЯХ, ОПОСРЕДОВАННЫХ NK-3 РЕЦЕПТОРАМИ, И ИХ ХИРАЛЬНЫЙ СИНТЕЗ |
| RU2637925C2 (ru) * | 2012-01-10 | 2017-12-08 | Ф. Хоффманн-Ля Рош Аг | Соединения тиенопиримидина |
| WO2014105958A2 (en) | 2012-12-26 | 2014-07-03 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
| JP5671192B2 (ja) | 2013-01-31 | 2015-02-18 | 帝人株式会社 | 圧電振動体 |
| TW201512189A (zh) * | 2013-04-16 | 2015-04-01 | Gruenenthal Chemie | 新型被取代之嘧啶縮合化合物 |
| ES2875548T3 (es) * | 2016-12-26 | 2021-11-10 | Meiji Seika Pharma Co Ltd | Compuesto novedoso y sal de este aceptable desde el punto de vista farmacológico |
| EP3684775B1 (en) | 2017-09-20 | 2024-11-20 | UNION therapeutics A/S | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors |
| WO2019115775A1 (en) | 2017-12-15 | 2019-06-20 | Leo Pharma A/S | Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitors |
| JP7198820B2 (ja) * | 2017-12-15 | 2023-01-04 | ユニオン・セラピューティクス・アクティエセルスカブ | 置換アゼチジンジヒドロチエノピリミジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用 |
| CN111727191B (zh) * | 2017-12-15 | 2024-01-05 | 联合疗法公司 | 取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其作为磷酸二酯酶抑制剂的用途 |
| CN111961034A (zh) * | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
| JP7772771B2 (ja) * | 2020-07-14 | 2025-11-18 | 武漢朗来科技発展有限公司 | Ｒｏｃｋ阻害剤及びその製造方法と用途 |
| CN119343352A (zh) * | 2022-06-02 | 2025-01-21 | 西藏海思科制药有限公司 | Pde4b抑制剂及其用途 |
| AU2023320795A1 (en) * | 2022-08-09 | 2025-02-27 | Xizang Haisco Pharmaceutical Co., Ltd. | Pde4b inhibitor and use thereof |
| US20260008788A1 (en) | 2022-09-29 | 2026-01-08 | Suzhou Ark Biopharmaceutical Co., Ltd. | Aza-fused ring compound, preparation method therefor, and use thereof in medicine |
| KR20250165661A (ko) | 2023-04-13 | 2025-11-26 | 상하이 이디 바이오테크놀로지 컴퍼니 리미티드 | 치환된 디히드로티오펜 병합 피리미딘류 화합물, 이의 제조 방법 및 용도 |
| WO2025038987A2 (en) * | 2023-08-17 | 2025-02-20 | Katalytic Therapeutics, Inc. | Pde4 protein degraders, pharmaceutical compositions, and therapeutic applications |
| WO2025067168A1 (zh) * | 2023-09-25 | 2025-04-03 | 苏州爱科百发生物医药技术有限公司 | 氮杂稠环类化合物及其制备方法和用途 |
| WO2025162431A1 (zh) * | 2024-02-04 | 2025-08-07 | 西藏海思科制药有限公司 | 一种pde4b抑制剂化合物的口服药物组合物及其制备方法 |
| TW202535412A (zh) * | 2024-02-04 | 2025-09-16 | 大陸商西藏海思科製藥有限公司 | Pde4b抑制劑的晶型及其在醫藥上的用途 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1470336A1 (de) | 1962-07-04 | 1969-03-20 | Thomae Gmbh Dr K | Neue Dihydrothieno-[3,4-d]-pyrimidine und Verfahren zu ihrer Herstellung |
| NL124131C (enExample) | 1963-06-17 | |||
| DE1470356A1 (de) | 1964-01-15 | 1970-04-30 | Thomae Gmbh Dr K | Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| BE754606A (fr) | 1969-08-08 | 1971-02-08 | Thomae Gmbh Dr K | Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication |
| DE2032687A1 (en) | 1970-07-02 | 1972-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Cardiovascular 2-aminoalkylamino-thienopyrimidines - and 4-morpholino derivatives from 4-diethanolamino-compounds by intramolecular cyclisa |
| DE1940572A1 (de) | 1969-08-08 | 1971-02-11 | Thomae Gmbh Dr K | Neue 2-Aminoalkylamino-thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung |
| US3763156A (en) | 1970-01-28 | 1973-10-02 | Boehringer Sohn Ingelheim | 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines |
| FR2082496A5 (enExample) | 1970-03-18 | 1971-12-10 | Westinghouse Freins & Signaux | |
| DE2121950A1 (en) | 1971-05-04 | 1972-11-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Thieno(3,2-d)pyrimidine derivs - with thrombocyte aggregation inhibiting activity |
| DE2750288A1 (de) | 1977-11-10 | 1979-05-17 | Thomae Gmbh Dr K | Neue 9-(omega-heteroarylamino- alkylamino)-erythromycine, ihre salze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel |
| US4256737A (en) | 1979-06-11 | 1981-03-17 | Syntex (U.S.A.) Inc. | Long acting depot injectable formulations for LH-RH analogues |
| US5187168A (en) | 1991-10-24 | 1993-02-16 | American Home Products Corporation | Substituted quinazolines as angiotensin II antagonists |
| JPH07330777A (ja) | 1994-06-08 | 1995-12-19 | Taisho Pharmaceut Co Ltd | チエノ［３，２−ｄ］ピリミジン−４−オン誘導体 |
| JPH09301958A (ja) | 1996-05-09 | 1997-11-25 | Nippon Shoji Kk | 新規ピリミジン化合物及び抗ロタウイルス剤 |
| US6339089B2 (en) | 1997-08-13 | 2002-01-15 | Fujirebio Inc. | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same |
| DE10064994A1 (de) | 2000-12-23 | 2002-07-04 | Merck Patent Gmbh | Sulfamidothienopyrimidine |
| CN101100472A (zh) * | 2001-04-30 | 2008-01-09 | 美国拜尔公司 | 4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物及其应用 |
| US6587548B2 (en) | 2001-07-17 | 2003-07-01 | Hewlett-Packard Development Co., L.P. | Method and system of using a single telephone number for multiple services |
| WO2003055890A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| JP4505228B2 (ja) | 2002-01-10 | 2010-07-21 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | Ｒｈｏ−キナーゼ阻害剤 |
| CA2523831C (en) | 2003-04-29 | 2008-11-18 | Pfizer Inc. | 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension |
| JP2005003345A (ja) | 2003-05-21 | 2005-01-06 | Showa Denko Kk | 換気兼熱交換装置および空調システム |
| KR20130041366A (ko) | 2003-10-02 | 2013-04-24 | 마텍 바이오싸이언스스 코포레이션 | 변형량의 염소 및 칼륨을 사용하는 미세조류 중에 고농도 디에치에이의 생산 |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| PL1874781T3 (pl) | 2006-04-19 | 2009-12-31 | Boehringer Ingelheim Int | Dihydrotienopirymidyny do leczenia chorób zapalnych |
| EP1847543A1 (de) * | 2006-04-19 | 2007-10-24 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen |
| CA2684659C (en) | 2007-04-20 | 2015-11-24 | Glaxo Group Limited | Tricyclic nitrogen containing compounds as antibacterial agents |
| US8653282B2 (en) | 2007-10-18 | 2014-02-18 | Boehringer Ingelheim International Gmbh | Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein |
| EP2214673B1 (de) | 2007-10-19 | 2012-05-30 | Boehringer Ingelheim International GmbH | Phenyl-substituierte piperazino-dihydrothienopyrimidine |
| JP5563466B2 (ja) | 2007-10-19 | 2014-07-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ピペラジノ−ジヒドロチエノピリミジン誘導体 |
| ES2565983T3 (es) | 2007-10-19 | 2016-04-08 | Merck Sharp & Dohme Corp. | Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad quinesina de KSP |
| FR2922550B1 (fr) | 2007-10-19 | 2009-11-27 | Sanofi Aventis | Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet |
| TW200934771A (en) | 2007-10-19 | 2009-08-16 | Astrazeneca Ab | New compounds |
| DK2610258T3 (da) | 2007-10-19 | 2014-11-10 | Boehringer Ingelheim Int | Substituerede piperidindihydrothienopyrimidiner |
| CN101827853A (zh) | 2007-10-19 | 2010-09-08 | 贝林格尔.英格海姆国际有限公司 | 杂环取代的哌嗪子基-二氢噻吩并嘧啶 |
| WO2010097334A1 (de) | 2009-02-27 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids |
| JP2012519159A (ja) | 2009-02-27 | 2012-08-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅ４阻害剤及びｎｓａｉｄを含有する複合薬 |
| US20130059866A1 (en) | 2011-08-24 | 2013-03-07 | Boehringer Ingelheim International Gmbh | Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma |
-
2008
- 2008-10-16 JP JP2010529385A patent/JP5563466B2/ja active Active
- 2008-10-16 CA CA2702518A patent/CA2702518A1/en not_active Abandoned
- 2008-10-16 EP EP08840365A patent/EP2215093B1/de active Active
- 2008-10-16 US US12/738,425 patent/US8486948B2/en active Active
- 2008-10-16 WO PCT/EP2008/063970 patent/WO2009050236A1/de not_active Ceased
- 2008-10-16 AT AT08840365T patent/ATE537175T1/de active
-
2013
- 2013-06-06 US US13/911,712 patent/US9090626B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20110046096A1 (en) | 2011-02-24 |
| US8486948B2 (en) | 2013-07-16 |
| EP2215093A1 (de) | 2010-08-11 |
| JP2011500638A (ja) | 2011-01-06 |
| WO2009050236A1 (de) | 2009-04-23 |
| US9090626B2 (en) | 2015-07-28 |
| EP2215093B1 (de) | 2011-12-14 |
| US20130274264A1 (en) | 2013-10-17 |
| CA2702518A1 (en) | 2009-04-23 |
| JP5563466B2 (ja) | 2014-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE537175T1 (de) | Neue piperazino-dihydrothienopyrimidin-derivate | |
| MY167135A (en) | Fused heterocyclic derivatives and methods of use | |
| EA200870193A1 (ru) | Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение | |
| MX2009009238A (es) | Nuevos inhibidores de fosfodiesterasa. | |
| MY159615A (en) | Fused heterocyclic derivatives and methods of use as c-met inhibitors | |
| AU2009258496A8 (en) | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity | |
| MY148688A (en) | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors | |
| MX340965B (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
| EA200702200A1 (ru) | Дигидротиенопиримидины для лечения воспалительных заболеваний | |
| MX2010002353A (es) | Amidas heterociclicas utiles para tratamiento de cancer y psoriais. | |
| NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
| ZA200810113B (en) | Method for the treatment and prevention of ocular disorders | |
| MX2009006543A (es) | Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer. | |
| DE602007014186D1 (de) | Triazin-11-beta-hydroxysteroid-dehydrogenase-artige hemmer | |
| GEP20084551B (en) | 4-phenylamino-quinazolin-6-yl-amides | |
| MA30821B1 (fr) | Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes | |
| MX2009011749A (es) | Compuestos triciclicos como inhibidores de metaloproteinasa matricial. | |
| MX2010001020A (es) | Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas. | |
| ATE446089T1 (de) | 2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika | |
| UA96304C2 (en) | 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | |
| IL195016A0 (en) | 1h-indol-5-yl-piperazin-1-yl-methanone derivatives | |
| MX2007004248A (es) | Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa. | |
| EA200901474A1 (ru) | Соли [4-(6-фтор-7-метиламино-2,4-диоксо-1,4-дигидро-2н-хиназолин-3-ил)фенил]-5-хлортиофен-2-илсульфонилмочевины в различных кристаллических формах и фармацевтические композиции на их основе | |
| UA96969C2 (en) | Acylaminopyrazoles as fgfr inhibitors | |
| TW200806321A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders |